...restored normal PGRN levels in FTD patients. The data were presented Wednesday at the 2019 Alzheimer's Association...

...MCI) or mild to moderate dementia due to Alzheimer's disease. Data were presented at the Alzheimer's Association...
...Phase II data Milestone: NA Chris Lieu elenbecestat (E2609) Biogen Inc. Eisai Co. Ltd. Beta-site APP-cleaving enzyme 1 (BACE1) Alzheimer's disease (AD) Alzheimer's Association...

...Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 at the Alzheimer's Association...
...in brain amyloid levels Status: Additional Phase II data Milestone: NA Erin McCallister BAN2401 Biogen Inc. Eisai Co. Ltd. Beta amyloid Alzheimer's Association's...

...Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 Wednesday at the Alzheimer's Association...
...BioArctic AB (SSE:BIOA B), which lost SEK6 to SEK151 on Wednesday. Erin McCallister BAN2401 Biogen Inc. Eisai Co. Ltd. Beta amyloid Alzheimer's Association's...

...week 12 vs. placebo. Boehringer plans to present full data from the trials at the Alzheimer's Association...

...week 12 vs. placebo. Boehringer plans to present full data from the trials at the Alzheimer's Association...

...of the study's patients were receiving LMTX as monotherapy. The TRx-237-015 data were presented at Alzheimer's Association...

...misuse of the IPR proceedings." Companies and Institutions Mentioned Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Alzheimer's Association...
...As of Sept. 3, at least 100 patient groups had signed the letter, including the Alzheimer's Association...

...management (see BioCentury, Feb. 4, 2013) . Data from Lilly's trial were presented at the Alzheimer's Association...
...plan to conduct its own CMS-approved CED study. In response to CMS's CED policy, the Alzheimer's Association...

...patients who delayed treatment by 80 weeks. In an abstract from a presentation at the Alzheimer's Association...
...of delayed-start analysis to determine the long-term efficacy and disease-modifying effects of AD treatments. The Alzheimer's Association...